SPY458.79+5.37 1.18%
DIA352.82+6.58 1.90%
IXIC15,225.15+139.68 0.93%

Barclays Maintains Overweight on GoodRx Holdings, Raises Price Target to $47

Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from $45 to $47.

Benzinga · 11/11/2021 07:10
Barclays analyst Steve Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from $45 to $47.